What’s Next in ALL Treatment: CAR T and Emerging Therapies image

What’s Next in ALL Treatment: CAR T and Emerging Therapies

Aug 22, 2025
02:30PM - 03:30PM EDT
Online Event
Overview

Join leukemia expert Dr. Jae Park for a patient-friendly overview of the latest treatment advances in acute lymphoblastic leukemia (ALL). Learn how CAR T-cell therapy works, who may qualify, and where it stands today—including clinical trials and future options. We’ll also explore other promising therapies like bispecific antibodies and how patients can access emerging treatments.

At the end of the session, you’ll have a chance to ask your questions directly to Dr. Park and connect with others in the ALL community.

 

Agenda
2:30 PM
Introduction
Marilú Nájera Flores

Marilu introduces the agenda of the event and our guest speaker Jae Park, MD

2:35 PM
Presentation
Hannah Husby and Peter Adintori 

Dr. Park talks about CAR T treatment

3:05 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them!

Speakers & Moderators
Healthtree contact Marilú Nájera Flores

Marilú Nájera Flores

Marilu Najera is an International Medical Graduate and an Event Operations Manager at the HealthTree Foundation. Her journey through several patient-centered roles has deepened her passion for advocacy, education, and connection. Now, as part of the education team, she is leading efforts to grow HealthTree’s newest community: ALL (acute lymphoblastic leukemia). She organizes patient-friendly webinars with expert speakers and works to ensure that patients and families feel informed, empowered, and supported. Marilu brings empathy, joy, and warmth to every project. Outside of work, she loves to travel, connect with others, and spend time with her loved ones—especially her nephews (being an aunt is her absolute favorite role in life!).
Healthtree contact Jae Park, MD

Jae Park, MD

Dr. Jae Park is a leukemia specialist and Director of the Adult ALL Program at Memorial Sloan Kettering Cancer Center. He is internationally recognized for his work in CAR T-cell therapy and other emerging treatments for blood cancers. His research focuses on improving therapies for patients with ALL through clinical trials and innovative immunotherapies.